Recent Updates
Recently added Catalysts

Briquilimab

Phase 2

Urticaria Chronic | Small molecule | Dermatology |Jasper Therapeutics, Inc.|Last Updated: Feb 23, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment67
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06736262A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria TrialsPHASE2 ACTIVE NOT_RECRUITING 67 — — Nov 26, 2024Sep 30, 2026Feb 23, 202619 United States, Germany
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
To evaluate the safety and tolerability of briquilimab
From signing the informed consent form through study completion (an average of one year)

Incidence and severity of AEs including SAEs, TEAEs and AEIs.

Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
BriquilimabEXPERIMENTALBriquilimab via SQ injection
Interventions
NameTypeDescription
BriquilimabDRUGNo additional details needed
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites19

Inclusion Criteria: 1. Provides informed written consent. 2. Previously participated in and completed an eligible Jasper-sponsored clinical trial (in the last 4 months) without any investigational product (IP)-related anaphylactic event 3. Disease specific eligibility: 1. Participants with CSU ...

Countries:United StatesGermany
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06736262primaryCompletionDate: changed
LOWMay 24, 2026NCT06736262studyFirstPostDate: changed